Dyadic Announces Sale of Equity Interest in Alphazyme

by B2i | Jan 19, 2023 | Press Releases

JUPITER, Fla., Jan. 19, 2023 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...

Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference

by B2i | Jan 4, 2023 | Press Releases

Dyadic’s executive management to attend the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and Investment Conference from January 8-12 in San Francisco, CA USAJUPITER, Fla., Jan. 04, 2023 — Dyadic International,...

Dyadic’s DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal

by B2i | Dec 14, 2022 | Press Releases

“Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge” Study supports: Dyadic’s anticipated First-In-Human clinical trial...

Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments

by B2i | Nov 10, 2022 | Press Releases

Received regulatory approval from South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 clinical trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19 recombinant protein RBD booster vaccine...

Dyadic to Present at Upcoming Industry and Investor Events in November

by B2i | Nov 7, 2022 | Press Releases

JUPITER, Fla., Nov. 07, 2022 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...